FGFR2 fusions and ERRFI mutations may represent novel targets in sporadic intrahepatic cholangiocarcinoma and trials should be characterized in larger cohorts of patients with these aberrations. The gene discussed is FGFR2; the disease is intrahepatic cholangiocarcinoma.